# reload+after+2024-01-23 10:46:44.712581
address1§Clarence Thomas Building
address2§P.O. Box 4649 Road Town
city§Tortola
zip§VG1110
country§British Virgin Islands
phone§203 221 7378
website§https://www.portagebiotech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
fullTimeEmployees§7
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ian B. Walters M.B.A., M.D.', 'age': 55, 'title': 'CEO & Chairman of Board', 'yearBorn': 1968, 'fiscalYear': 2023, 'totalPay': 967651, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Allan J. Lee Shaw CPA', 'age': 59, 'title': 'Chief Financial Officer', 'yearBorn': 1964, 'fiscalYear': 2023, 'totalPay': 524081, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven  Innaimo', 'title': 'Vice President of Project Management & Operations', 'fiscalYear': 2023, 'totalPay': 444057, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert A. Kramer Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2023, 'totalPay': 310157, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian  Wiley', 'age': 55, 'title': 'Chief Business Officer', 'yearBorn': 1968, 'fiscalYear': 2023, 'totalPay': 220688, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Justin  Fairchild', 'title': 'Vice President of Development', 'fiscalYear': 2023, 'totalPay': 283831, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph  Ciavarella', 'title': 'Chief Accounting Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§92.583
currency§USD
dateShortInterest§1702598400
forwardEps§-1.31
exchange§NCM
quoteType§EQUITY
shortName§Portage Biotech Inc.
longName§Portage Biotech Inc.
firstTradeDateEpochUtc§1009981800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c85b618a-5b14-3e35-9d8d-d4e5ddb2236b
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§6.0
targetMeanPrice§6.0
targetMedianPrice§6.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§1.115
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
